GSK's Synflorix vaccine premieres in South Asia; Oxford BioMedica abandons mid-stage clinical trial of cancer vax TroVax;

 @AlisonBFierce: A new study shows the safety of Inovio Pharmaceutical's experimental vaccine for people who already have HPV. More | Follow @AlisonBFierce

> A Chinese-made vaccine is on the verge of being approved for aid agency use by the World Health Organization. Story

> Immunovaccine reported positive interim results from a Phase I study of an ovarian cancer vaccine candidate, DPX-Survivac. Release

> The CDC is looking to increase the vaccination rates for physicians during the 2012-2013 flu season. Report

> Pakistan became the first country in South Asia to introduce GlaxoSmithKline's ($GSK) Synflorix vaccine against pneumococcal disease in children. News

> Novavax began enrollment in its Phase II RSV vaccine trial. More

And Finally... Britain's Oxford BioMedica closed a mid-stage clinical trial of its cancer vaccine TroVax in U.S. patients with prostate cancer, dealing another blow to the troubled product. Item | More

Suggested Articles

CEPI, which started to help prepare the world for new outbreaks, has awarded Inovio and Moderna money for vaccine work against the new coronavirus.

As a new coronavirus spreads, vaccine researchers have started work on candidates against the virus—and one could enter the clinic in a few months.

Merck's HPV vaccine Gardasil is delivering blockbuster sales as demand surges. But high demand has caused somewhat of a supply constraint.